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Adjuvant treatment of colon cancer has been a clear
success story over the last three decades. Since the seminal
trial of Moertel demonstrating the efﬁcacy of 5-ﬂuorouracil
(5-FU) with levamisole for stage III disease, to the current
standard of care of oxaliplatin plus ﬂuoropyrimidines
delivered either as the FOLFOX or the XELOX regimen, a
large number of randomized clinical trials have supported
incremental advances in efﬁcacy as well as modiﬁcations
to retain efﬁcacy while reducing toxicity and/or duration of
therapy.
1–3 The Colon Clinical Trials Program of the
National Surgical Adjuvant Breast and Bowel Project
(NSABP) has been a fundamental cog in this wheel; many
of the NSABP’s trials have helped set or validate a stan-
dard of care. As such, it is useful to review the history of
the NSABP’s trial program, which Wilkinson et al. do in
this issue.
4
The pooled results of NSABP C-01 through C-05 reaf-
ﬁrm several facts. First, and most importantly, ﬂuorouracil-
based adjuvant therapy provides clear, clinically mean-
ingful beneﬁt to patients with stage III colon cancer. That
this message warrants repeating is surprising, as it comes
20 years after the National Cancer Institute consensus
statement.
5 However recent population-based data continue
to demonstrate that, in the USA, up to 30% of the stage III
colon cancer population is not treated with adjuvant ther-
apy.
6 The reduced use of chemotherapy is particularly
pronounced in the elderly, despite meta-analyses of ran-
domized trials that demonstrated a similar beneﬁt from
chemotherapy in both young and older (age C70 years)
patients.
6,7
Second, the analysis conﬁrms a more recent realization
that the mechanism of beneﬁt of 5-FU-based therapy is to
dramatically reduce the recurrence rate in the ﬁrst 2 years
post surgery, which is when most recurrences occur. This
short-term reduction in the recurrence risk translates into a
durable survival beneﬁt.
8 This phenomenon was conﬁrmed
in this NSABP analysis, where in the ﬁrst year post sur-
gery, chemotherapy reduced the risk of recurrence in stage
III patients from 20% to 10% and from 21% to 15% in year
2. Following year 2, the recurrence risk was similar in
chemotherapy-treated and control patients. This observa-
tion is critical for modern clinical trials, as it relates to both
the optimal endpoint for a phase III adjuvant trial as well as
the underlying biologic mechanism for beneﬁt of a new
therapy. Regarding the ﬁrst point, for trials testing cyto-
toxic agents expected to have a similar antitumor effect to
chemotherapy, this suggests that an early time point such
as 2 or 3 years may be the most sensitive time point to
identify a true biologic drug effect.
9,10 With regard to the
underlying biologic mechanism of action of an adjuvant
cytotoxic therapy such as 5-FU, it clearly reduces the risk
of recurrent disease, as opposed to only delaying its
occurrence. As such this therapy actually eradicates
micrometastatic disease, a prerogative for a curative effect.
A similar mechanism of action appears to be present for the
addition of oxaliplatin to 5-FU; at 5- and 6-year follow-up
in the more recent MOSAIC and NSABP C-07 trials the
survival curves are continuing to separate and no increase
in late recurrences has been observed.
11,12 However, in the
recent NSABP C-08 trial which added the noncytotoxic,
biologic agent bevacizumab to FOLFOX, only a short-term
beneﬁt in reduction of recurrence risk was observed, which
disappeared after bevacizumab was halted, such that at 3-
year follow-up the disease-free survival rates were almost
identical in the two arms.
13 Thus, in trials of agents with
noncytotoxic mechanism of action, short-term endpoints
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equate to assess long-term survival beneﬁts, as recurrences
that are simply delayed as opposed to prevented will not
result in long-term cure.
The report of Wilkinson et al. also provides data
regarding the beneﬁt of 5-FU-based adjuvant therapy in
patients with stage II disease. Adjuvant therapy for patients
with stage II disease has been a long-standing controversy,
with primarily the NSABP advocating treatment and others
ﬁnding very little beneﬁt.
14,15 Fortunately, we now have
randomized data from a large single clinical trial, the recent
QUASAR study, where 5-FU-based chemotherapy was
associated with signiﬁcantly improved overall survival
(OS) compared with surgery alone in largely stage II
patients [5-year OS of 80.3% for chemotherapy versus
77.4% for observation; hazard ratio (HR) = 0.83, p =
0.02].
16 These data from a large single randomized trial
provide stronger evidence and a more accurate estimate of
the true beneﬁt than that possible from the pooled analysis
of trials presented by Wilkinson, in which no individual
trial directly tested intravenous 5-FU-based therapy against
surgery-alone control.
4 No amount of multivariate analysis
can adjust for the potential for bias in such a comparison,
particularly in one where the age distribution of the
included patients clearly changed over time; protocols C-
03 and C-04 excluded patients over the age of 71 years
whereas such patients were allowed in C-01 and C-02, the
former being the only two trials with no postsurgical
treatment control arms.
The high rate of cure from surgery alone in patients with
stage II disease dictates that any postoperative therapy
given will be unnecessary for most patients who are cured
by surgery alone. There is thus the critical need for prog-
nostic and predictive markers to identify which patients are
both at higher and very low risk of recurrence, and more
importantly which patients may beneﬁt from therapy. The
NSABP authors’ suggestion that ‘‘it is inconceivable that a
future RCT studying adjuvant therapy for stage II and III
colon cancer will ever include patients treated by surgery
alone or even surgery followed by 5-FU/LV’’ is an over-
statement given that such a phase III trial is ongoing within
the US Intergroup at the present time (ECOG E5202),
where patients with stage II colon cancer receive or do not
receive adjuvant therapy depending on their status on 18q
loss of heterozygosity (LOH) and microsatellite instability
(MSI). Indeed, the promising data available for MSI to
identify patients who are at very low recurrence risk and
who do not appear to beneﬁt from 5-FU support a no-
treatment approach in MSI-H stage II colon cancer
patients.
17–20 On the other hand, T4 N0 stage II colon
cancers have a prognosis similar to (or even worse than)
stage III cancers and should likely routinely receive adju-
vant therapy. For the remaining intermediate-risk patients
with stage II colon cancer, a signature of molecular makers
might be able to further characterize patients with regard to
their overall prognosis and whether or not they could
beneﬁt from a speciﬁc adjuvant treatment regimen.
17
Therefore, biospecimen resources to facilitate the identiﬁ-
cation and validation of prognostic and predictive markers,
such as those available at the NSABP, will be critical for
the future reﬁnement of adjuvant treatment strategies in
colon cancer.
Clinical trials continue to be the cornerstone of
advancing medical practice, and nowhere is this more clear
than in adjuvant colon cancer. The NSABP has and con-
tinues to conduct critical trials to advance our
understanding, and the data from these trials continue to
provide new insights many years after the primary ques-
tions are resolved.
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